Russian Heart Failure Journal 2009year Beta-adrenoblockers and the renal continuum


To access this material please log in or register

Register Authorize
2009/

Beta-adrenoblockers and the renal continuum

Arutyunov G. P., Oganezova L. G.

Keywords:

DOI:

Chronic heart failure is often associated with renal dysfunction. An important pathogenetic component of these conditions is overactivation of the sympathico-adrenal system (SAS). Thus the present review discusses the issue of efficacy and safety of β-adrenoblockers (BAB) in this patient population. Review provides results of the largest studies (COMET, PRIME-II, SOLVD Prevention and Treatment, CIBIS-II and CIBIS-III) evaluating the effect of BAB on prognosis in patients with CHF and chronic renal disease.
  1. Salomonsson M, Brännström K, Arendshorst WJ. lpha (1) – adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol Renal Physiol. 2000; 278 (1):F138-147.
  2. Moss NG, Colinders RE, Gottschalk CW. Neural control of renal function. In Windhager E. E. «Renal physiology» NY, Oxford University Press 1992, chapter 22.
  3. Арутюнов Г. П. «Патофизиологические процессы в почках у больных хронической сердечной недостаточностью». Журнал Сердечная Недостаточность. 2008; 9 (5):234‑250.
  4. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997; 51 (3):722‑727.
  5. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995; 25 (4 Pt 2):878‑882.
  6. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002; 15 (8):717‑724.
  7. Salplachta J, Bartosíková L, Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys. 2002; 21 (2):189‑195.
  8. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant. 1996; 11 (6):1003–1011.
  9. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol. 2005; 63 (6):446‑453.
  10. Amann K, Ritz E. Microvascular disease--the Cinderella of uraemic heart disease. Nephrol Dial Transplant. 2000; 15 (10):1493–1503.
  11. Cice G, Ferrara L, D’Andrea A et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003; 41 (9):1438–1444.
  12. Mann JF, Jakobs KH, Riedel J, Ritz E. Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol. 1986; 250 (5 Pt 2):H846-852.
  13. Leineweber K, Heinroth-Hoffmann I, Pönicke K et al. Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol. 2002; 13 (1):117‑124.
  14. Rascher W, Schömig A, Kreye VA, Ritz E. Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int. 1982; 21 (1):20–27.
  15. Converse RL Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992; 327 (27):1912–1918.
  16. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999; 340 (17):1321–1328.
  17. Klein IH, Ligtenberg G, Oey PL et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427–2433.
  18. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974–1979.
  19. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardio-vascular events in patients with end-stage renal disease.Circulation.2002; 105:1354–9.
  20. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004; 19 (7):1829–1834.
  21. Zuanetti G, Maggioni AP, Keane W, et al. Nephrologists neglect administration of beta-blockers to dialysed diabetic patients. Nephrol Dial Transplant. 1997; 12:2497–500.
  22. Chobanian AN, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003; 289 (19):2560–2572.
  23. Antman EM, Anbe DT, Armstrong PW et al. ACC / AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004; 110 (5):588‑636.
  24. Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998; 19 (5):696‑710.
  25. Parameshwar J, Keegan J, Sparrow J et al. Predictors of prognosis in severe chronic heart failure. Am Heart J. 1992; 123 (2):421‑426.
  26. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001; 38 (7):1782–1787.
  27. Hampton JR, Van Veldhuisen DJ, Kleber FX et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME-II) Investigators. Lancet. 1997; 349 (9057):971‑977.
  28. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000; 102 (2):203‑210.
  29. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992; 70 (4):479‑487.
  30. Leithe ME, Margorien RD, Hermiller JB et al. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984; 69 (1):57–64.
  31. Elsner D. Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Eur Heart J. 1995; 16 (Suppl N):52–58.
  32. Krumholz HM, Chen YT, Vaccarino V et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000; 85 (9):1110–1113.
  33. Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35 (3):681‑689.
  34. Smith GL, Vaccarino V, Kosiborod M et al. Wosening renal function what is a clinically meaningful change in creatinine during hospitalization with HF. J Card Fail. 2003; 9 (1):13–25.
  35. Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002; 8 (3):136‑141.
  36. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43 (1):61–67.
  37. Erdmann E, Lechat P, Verkenne P et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001; 3 (4):469‑479.
  38. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130 (6):461‑470.
  39. Abraham WT, Tsvetkova T, Lowes BD et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation. 1998; 98 (Suppl I):I-378-379.
  40. Komajda M, Lutiger B, Madeira H et al. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004; 6 (4):467-475.
  41. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995; 47 (3):884-890.
  42. Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980; 112 (6):736-749.
  43. Beddhu S, Nigwekar SU, Ma X, Greene T. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2009 Mar 22. [Epub ahead of print].

To access this material please log in or register

Register Authorize
Ru En